Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Stargardt Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

RayTx Clinical Site, Bakersfield, California, United States
UPMC Vision Institute, Pittsburgh, Pennsylvania, United States
Contact: Study coordinator (UPMC Vision Institute Clinical Trials Team) · Clinicaltrialsoph@upmc.edu · 412-642-7888
RayTx Clinical Site, Bellaire, Texas, United States

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

Stargardt Disease

Abroad (travel likely)RecruitingPHASE1, PHASE2

Phoenix, United States · Los Angeles, United States

Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)

Retinal Dystrophy Due to Biallelic ABCA4 Mutations · Stargardt Disease 1

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shanghai, China

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

Stargardt Disease · Cone Rod Dystrophy · Juvenile Macular Degeneration

Abroad (travel likely)RecruitingPHASE1, PHASE2

San Francisco, United States · Gainesville, United States

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

Stargardt Disease · Stargardt Macular Degeneration · Stargardt Macular Dystrophy

Abroad (travel likely)RecruitingPHASE1, PHASE2

Aurora, United States · Miami, United States